Genetic Technologies (AU:GTG) has released an update.
Genetic Technologies Limited (GTG) has announced a partnership with CancerIQ, integrating GTG’s geneType Risk Assessment Tests into the CancerIQ platform, which serves over 45 healthcare systems and 250 clinics. This collaboration aims to enhance cancer prevention by identifying high-risk patients across a wider network, leveraging CancerIQ’s significant adoption in clinical settings for improved health outcomes. GTG anticipates increased visibility and accessibility of its tests in the U.S. healthcare market, aligning with its mission of personalized cancer prevention.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
